Anti-NRP1 peptide-engineered ROS/pH dual-responsive nanoparticles for Alpelisib delivery regulate Sema3A-NRP1/PI3K-AKT signaling to balance oxidative stress and inhibit angiogenesis in endometriosis -
4 hours ago
- #endometriosis
- #nanomedicine
- #angiogenesis
- Designed anti-NRP1 peptide-engineered ROS/pH dual-responsive nanoparticles for targeted delivery of Alpelisib to treat endometriosis.
- Nanoparticles showed responsive drug release, stability, and selective internalization in NRP1-overexpressing endothelial cells.
- In vitro, treatment inhibited NRP1/PI3K-AKT signaling, reduced ROS, and increased antioxidant enzyme activities.
- In a rat model, nanoparticles reduced ectopic lesion burden, angiogenesis markers (VEGF, CD34), inflammation, and oxidative injury.
- Fluorescence imaging confirmed nanoparticle accumulation in vascular regions, modulating Sema3A-NRP1-PI3K/AKT to restore redox balance.